|
ORC2L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.96509475358653E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
4.18220014175574E-10 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
7.7715611723761E-16 |
| Stage1-vs-Stage2 |
8.379400E-01 |
| Stage1-vs-Stage3 |
4.476000E-02 |
| Stage1-vs-Stage4 |
2.548000E-02 |
| Stage2-vs-Stage3 |
1.330150E-01 |
| Stage2-vs-Stage4 |
5.582000E-02 |
| Stage3-vs-Stage4 |
5.191200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.99200722162641E-15 |
| Normal-vs-AfricanAmerican |
1.56990999999884E-05 |
| Normal-vs-Asian |
1.62779789647516E-11 |
| Caucasian-vs-AfricanAmerican |
8.724000E-02 |
| Caucasian-vs-Asian |
4.858800E-01 |
| AfricanAmerican-vs-Asian |
3.055600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.095800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.2490009027033E-13 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.63735691671718E-12 |
| Normal-vs-Age(81-100Yrs) |
2.3695999999962E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.466200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.958400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.706000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.301000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.343200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.212200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.080900E-03 |
| Classical-VS-Follicular |
9.271000E-01 |
| Classical-VS-Other |
4.461800E-01 |
| Classical-VS-Normal |
1.22002408176058E-12 |
| Tall-VS-Follicular |
4.415400E-03 |
| Tall-VS-Other |
4.183200E-01 |
| Tall-VS-Normal |
9.99200722162641E-16 |
| Follicular-VS-Other |
5.410800E-01 |
| Follicular-VS-Normal |
1.02150510272736E-11 |
| Other-VS-Normal |
2.604800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.21014309684142E-14 |
| N0-vs-N1 |
2.604600E-01 |
|
|
